JAMA/ LinkedIn
Sep 1, 2025, 07:40
JAMA: Semaglutide and Tirzepatide Reduce Heart Failure Risk in Patients With HFpEF
Journal of the American Medical Association (JAMA) made a noteworthy post on LinkedIn:
“In patients with cardiometabolic HFpEF, semaglutide and tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but tirzepatide offered no additional benefit over semaglutide.”
Read the full article here:
Article: Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
Authors: Nils Krüger, Sebastian Schneeweiss, Kenshiro Fuse, Sofiya Matseyko, Sushama Kattinakere Sreedhara, Georg Hahn, Heribert Schunkert, Shirley V. Wang
Follow the newest insights in hematology with Hemostasis Today.
-
Mar 9, 2026, 16:51Melanie Daniel: Exploring Bleeding Complications in Patients with LVADs
-
Mar 9, 2026, 16:30Mohamed Sikkander Abdul Razak: Recent Breakthroughs in Stem Cell Therapy for Diabetes Treatment
-
Mar 9, 2026, 16:28Augustina Isioma Ikusemoro: Is Blood Really Affordable?
-
Mar 9, 2026, 16:26Todd Maderis: Great Conversation on Effective Treatment of Chronic Infections
-
Mar 9, 2026, 16:25Denise Braendgaard: How Partnership is Turning Ambition Into Action
-
Mar 9, 2026, 16:10Veronica Sanchez: Recognizing the Risks of Preeclampsia During Pregnancy and Newly Postpartum
-
Mar 9, 2026, 16:06Abdul Mannan: Explaining the Molecular Mechanism Behind VITT
-
Mar 9, 2026, 16:03Wathsala Manindrani: Managing Severe Hypertriglyceridemia in Resource-Limited Settings
-
Mar 9, 2026, 15:55Honoring the Volunteers, Advocates, and Families Driving Awareness and Research of Glanzmann Thrombasthenia – GRF